Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2023

Summary of Significant Accounting Policies

Schedule of anti-dilutive common stock equivalents excluded from the calculation of diluted net loss per share

	Year Ended December 31,
	2023	2022
Series X Preferred Stock	5,184,591	5,242,501
Stock options	3,553,969	2,253,431
Common stock warrants	7,700,596	1,530,176
	16,439,156	9,026,108

Schedule of condensed consolidated statement of cash flows

The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet that sum to the total of the same such amount shown in the statement of cash flows is as follows (in thousands):

	December 31,
	2023		2022
Cash and cash equivalents	$	175,530	$	20,525
Restricted cash (1)		163		163
Total	$	175,693	$	20,688

(1)Included as a component of prepaid expenses and other current assets at December 31, 2023 and other long-term assets at December 31, 2022.

Schedule of stock-based compensation expense

During the years ended December 31, 2023 and 2022, the Company recorded stock-based compensation expense for employee and non-employee stock options and restricted stock, which was allocated as follows in the statements of operations (in thousands):

	Year Ended December 31,
	2023		2022
Research and development	$	1,304	$	1,318
General and administrative		5,010		3,236
Total	$	6,314	$	4,554